CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Rhea-AI Summary

CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, has announced an upcoming plenary presentation at the 30th International AKI & CRRT Conference in San Diego.

The company's Chief Medical Officer, Dr. Sudarshan Hebbar, will present on 'The Role of ORAI-1 in AKI' during the 'Bench to Bedside: Translating Discoveries to Clinical Care' session on March 3, 2025, at 10:35 AM PT.

LA JOLLA, Calif., Feb. 19, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30^th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.

Details for the presentation are as follows:

Presentation Title: The Role of ORAI-1 in AKI

Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica

Session Title: Plenary 2: Bench to Bedside: Translating Discoveries to Clinical Care

Session Date and Time: Monday, March 3, 10:35-10:55 a.m. PT

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.

Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-plenary-presentation-at-the-30th-international-aki--crrt-conference-302379681.html

SOURCE CalciMedica, Inc.

FAQ

When is CalciMedica (CALC) presenting at the 30th International AKI & CRRT Conference?

CalciMedica is presenting on March 3, 2025, at 10:35 AM PT during the conference in San Diego, CA.

What is the topic of CalciMedica's (CALC) presentation at the AKI & CRRT Conference 2025?

The presentation is titled 'The Role of ORAI-1 in AKI' and will be delivered during the 'Bench to Bedside: Translating Discoveries to Clinical Care' session.

Who will be presenting for CalciMedica (CALC) at the 2025 AKI & CRRT Conference?

Dr. Sudarshan Hebbar, CalciMedica's Chief Medical Officer, will be delivering the plenary presentation.

What type of therapies is CalciMedica (CALC) developing?

CalciMedica is developing CRAC (calcium release-activated calcium) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.